Company
OTCMKTS: EMMA
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease. The company currently markets U.S. Food and Drug Administration approved Endari® (L-glutamine oral powder) indicated to reduce the acute complications of sickle cell disease in adults and children 5 years and older. The company is also engaged in the discovery and development of innovative treatments and therapies for certain rare and orphan diseases as well as those affecting larger populations, such as diverticulosis. For more information, please visit www.emmausmedical.com .
27 stories · page 2 of 2
The company achieved net income status two years after entering its commercial stage and aspires for continued growth and expansion in the coming years, to be profitable and to be able to provide dividends
Analysis of the Phase 3 data indicated that patients who got blood transfusions required 43% fewer units of red blood cells when treated with Endari
The revenue figure was up 3% from the $5.6 million it posted during the same period last year
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
“This partnership with UpScript, a proven, direct-to-consumer telehealth platform, provides us with another key avenue through which we can meaningfully improve sickle cell patients' access to Endari,” Emmaus chairman and CEO Dr Yutaka Niih
The Torrance, California-based company said that Asembia will provide a single point of contact for benefits investigation, financial and co-pay assistance, as well as patient and provider education
